Aprea Therapeutics

General Information


We are a clinical-stage biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. p53 is the protein expressed from the TP53 gene, the most commonly mutated gene in cancer. We believe that mutant p53 is an attractive therapeutic target due to the high incidence of p53 mutations across a range of cancer types and its involvement in key cellular activities such as apoptosis. Cancer patients with mutant p53 face a significantly inferior prognosis even when treated with the current standard of care, and a large unmet need for these patients remains.

Employees: 14
Founded: 2019
Contact Information
Address 535 Boylston Street, Boston MA 02116, US
Phone Number (617) 463-9385
Web Address http://www.aprea.com
View Prospectus: Aprea Therapeutics
Financial Information
Market Cap $298.1mil
Revenues $0 mil (last 12 months)
Net Income $-16.6 mil (last 12 months)
IPO Profile
Symbol APRE
Exchange NASDAQ
Shares (millions): 5.7
Price range $15.00 - $15.00
Est. $ Volume $85.0 mil
Manager / Joint Managers J.P. Morgan/ Morgan Stanley/ RBC Capital Markets
CO-Managers -
Expected To Trade: 10/3/2019
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change